SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Groenen LC, Nice EC, Burgess AW. Structure-function relationships for the EGF/TGF-alpha family of mitogens. Growth Factors. 1994; 11: 235257.
  • 2
    Lemke G. Neuregulins in development. Mol Cell Neurosci. 1996; 7: 247262.
  • 3
    Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987; 235: 177182.
  • 4
    Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244: 707712.
  • 5
    Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990; 8: 103112.
  • 6
    Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer. 1991; 63: 447450.
  • 7
    Toikkanen S, Helin H, Isola J, et al. Prognostic significance of HER2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol. 1992; 10: 10441048.
  • 8
    Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999; 26: 6070.
  • 9
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783792.
  • 10
    Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999; 17: 26392648.
  • 11
    Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999; 26: 7883.
  • 12
    Hudis C, Seidman A, Paton V, et al. Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials [abstract 24]. 21st Annual San Antonio Breast Cancer Symposium. Dec. 12–15, 1998, San Antonio, TX. Breast Cancer Res Treat. 1998; 50: 232.
  • 13
    Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998; 16: 26592671.
  • 14
    Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20: 23192326.
  • 15
    Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab (Herceptin) as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 719726.
  • 16
    Baselga J. Safety profile of Herceptin as a single agent and in combination with chemotherapy [abstract 1299]. Eur J Cancer. 1999; 35: S324.
  • 17
    Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol. 2001; 28: 2027.
  • 18
    Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001; 19: 25872595.
  • 19
    Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001; 19: 27222730.
  • 20
    Burris HA, 3rd. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol. 2001; 28: 3844.
  • 21
    Tjeerdsma G, Meinardi MT, van Der Graaf WT, et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart. 1999; 81: 419423.
  • 22
    Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998; 339: 900905.
  • 23
    Moreb JS, Oblon DJ. Outcome of clinical congestive heart failure induced by anthracycline chemotherapy. Cancer. 1992; 70: 26372641.
  • 24
    Strasser F, Betticher DC, Suter TM. Trastuzumab and breast cancer. N Engl J Med. 2001; 345: 996.
  • 25
    Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995; 378: 394398.
  • 26
    Fuchs I, Landt S, Buehler H, et al. HER2 expression in the myocardium as a cause for cardiotoxicity of trastuzumab (Herceptin)? [abstract 393]. Proc Am Soc Clin Oncol. 2000; 19: 102a.
  • 27
    Ewer MS, Gibbs HR, Swafford J, et al. Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol. 1999; 26: 96101.
  • 28
    Chien KR. Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Semin Oncol. 2000; 27: 914; discussion 92–100.
  • 29
    Chien KR. Stress pathways and heart failure. Cell. 1999; 98: 555558.
  • 30
    Committee on the Evaluation and Management of Heart Failure. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 1995; 26: 13761398.
  • 31
    HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. Heart Failure Society of America. Pharmacotherapy. 2000; 20: 495522.
  • 32
    Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91: 710717.
  • 33
    Valero V, Buzdar AU, Theriault RL, et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999; 17: 14251434.
  • 34
    Shapiro CL, Ervin T, Welles L, et al. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. J Clin Oncol. 1999; 17: 14351441.
  • 35
    Washington CB, Lieberman G, Liu P, et al. A population pharmacokinetic model for trastuzumab following weekly dosing [abstract]. Clin Pharmacol Ther. 2002; 71: 12.
  • 36
    Behr TM, Behe M, Wormann B. Trastuzumab and breast cancer. N Engl J Med. 2001; 345: 995996.